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All-trans-retinoic acid is a potent inhibitor of cell proliferation and inducer of differentiation. However, the clinical use of all-trans-
retinoic acid in the treatment of cancer is signiﬁcantly hampered by its toxicity and the prompt emergence of resistance, believed
to be caused by increased all-trans-retinoic acid metabolism. Inhibitors of all-trans-retinoic acid metabolism may therefore prove
valuable in the treatment of cancer. In this study, we characterize R116010 as a new anticancer drug that is a potent inhibitor of
all-trans-retinoic acid metabolism. In vitro, R116010 potently inhibits all-trans-retinoic acid metabolism in intact T47D cells with an
IC50-value of 8.7 nM. In addition, R116010 is a selective inhibitor as indicated by its inhibition proﬁle for several other cytochrome
P450-mediated reactions. In T47D cell proliferation assays, R116010 by itself has no effect on cell proliferation. However, in
combination with all-trans-retinoic acid, R116010 enhances the all-trans-retinoic acid-mediated antiproliferative activity in a
concentration-dependent manner. In vivo, the growth of murine oestrogen-independent TA3-Ha mammary tumours is
signiﬁcantly inhibited by R116010 at doses as low as 0.16 mg kg
71. In conclusion, R116010 is a highly potent and selective
inhibitor of all-trans-retinoic acid metabolism, which is able to enhance the biological activity of all-trans-retinoic acid, thereby
exhibiting antitumour activity. R116010 represents a novel and promising anticancer drug with an unique mechanism of action.
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All-trans-retinoic acid (RA) is a naturally occurring retinoid that is
well-known to inhibit cell proliferation and to induce differentia-
tion (Hong and Itri, 1994; Moon et al, 1994). However, the
clinical use of RA in the treatment of cancer is signiﬁcantly
hampered by the prompt emergence of resistance, which is believed
to be caused by increased RA metabolism (Muindi et al, 1992,
1994; Lee et al, 1993; Miller, 1998). RA is metabolized by
CYP26A1, an inducible cytochrome P450-dependent enzyme, that
inactivates RA by 4-hydroxylation of the b-ionone ring (White et
al, 1997). This tightly-controlled negative feedback mechanism
limits the availability of RA and thereby also its biological activity.
Therefore, increasing levels of RA by inhibition of its metabolism
might prove an innovative approach to cancer treatment.
Previously, we have identiﬁed liarozole-fumarate as an inhibitor
of RA metabolism (Wouters et al, 1992). In vitro, liarozole-fuma-
rate has been shown to enhance both the antiproliferative and
differentiation-inducing activity of RA (Wouters et al, 1992; Van
heusden et al, 1996, 1998). In vivo, liarozole-fumarate increases
endogenous RA levels both in plasma and tissues (Smets et al,
1995). In several preclinical tumour models, liarozole-fumarate
has been shown to exhibit antitumour activity (Van Ginckel et
al, 1990; Dijkman et al, 1994; Smets et al, 1995), linked to
increased levels of RA within the tumour (Smets et al, 1995). In
cancer patients, liarozole-fumarate has been shown to increase
the half-life of orally administered RA and 13-cis-retinoic acid
(Westarp et al, 1993; Achkar et al, 1994; Miller et al, 1994).
However, one of the limitations to the use of liarozole-fumarate
was its lack of speciﬁcity. It was shown to inhibit also other cyto-
chrome P450-mediated reactions (Vanden Bossche, 1992) and
affect plasma hormone levels in volunteers (Bruynseels et al, 1990).
This lack of speciﬁcity might partly explain the limited risk
beneﬁt ratio observed in cancer patients. A more potent and selec-
tive inhibitor is therefore required to improve the clinical efﬁcacy
of inhibitors of RA metabolism. In the present study, we identify
R116010 (Figure 1) as a highly potent and selective second-genera-
tion inhibitor of RA metabolism that induces antitumour activity.
MATERIALS AND METHODS
Drug and chemicals
R116010, [S-(R*,R*)]-N-[4-[2-(dimethylamino)-1-(1H-imidazole-
1-yl)propyl]-phenyl]-2-benzothiazolamine, and liarozole-fumarate,
+-5-[(3-chlorophenyl)(1H-imidazole-1-yl)methyl]-1H-benzimida-
zole (E)-2-butenedioate (2:3) were synthesized at the Department
of Medicinal Chemistry (Johnson & Johnson Pharmaceutical
Research & Development, Val-de-Reuil, France). Compounds were
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www.bjcancer.comdissolved to an initial concentration of 10 mM in DMSO. Further
dilutions were made in culture medium. [11, 12-
3H(N)]RA
(30 Ci mmol
71) was obtained from NEN Life Science Products
(Boston, MA, USA). Unlabelled RA was purchased from Serva
(Heidelberg, Germany) and dissolved to an initial concentration
of 4 mM in ethanol. Further dilutions were made in culture
medium. All-trans-retinoic acid was used in a dark-room with
yellow illumination. Final solvent concentrations in the in vitro
assays were always less than 0.5% (v/v). This solvent concentration
had no effect in the respective assays.
Cell culture
Human T47D breast cancer cells – purchased from the American
Type Culture Collection (Rockville, MD, USA) – were cultured in
RPMI 1640 medium supplemented with 10% (v/v) FBS, 2 mM L-
glutamine, 50 mgm l
71 gentamicin, and 10 mgm l
71 insulin (all
reagents from Life Technologies, Gent, Belgium). Cells were grown
in a humidiﬁed incubator (5% CO2, 95% air) at 378C and were
Mycoplasma-free as tested by the Mycoplasma T.C. kit (Gen-Probe
Incorporated, CA, USA).
Microcolumn assay for RA metabolism
RA metabolism was quantitatively determined using the microcol-
umn assay as described previously (Krekels et al, 1997). Brieﬂy,
T47D cells were pretreated for 16 h with 1 mM RA to induce RA
metabolism. Cells were then washed twice with culture medium,
harvested and resuspended at 4610
6 cells ml
71. An aliquot of this
cell suspension (450 ml) was incubated for 90 min in the presence of
0.1 mM [11, 12-
3H(N)]RA, after which 2 ml acetonitrile was added.
After centrifugation for 10 min at 780 g, the resulting deproteinized
supernatant was acidiﬁed with 2.5 ml of 40 mM acetic acid and
applied to a 3 ml C18 Bond Elut LRC column (Varian, Harbor City,
CA, USA; pretreated with 4 ml distilled water) under a vacuum of
127 mmHg using VAC ELUT SPS-24 and the efﬂuent was collected.
The column was eluted with 1 ml 40% acetonitrile and the efﬂuent
was collected in the same vial. Radioactivity in the collected efﬂuent,
containing the polar metabolites, was determined in a Packard Tri-
carb 4530 liquid scintillation analyzer. Optiphase ‘Hi Safe II’
(Wallac, Milton Keynes, UK) was used as a scintillator. Data are
presented as mean+s.d. of three or four independent experiments.
The IC50-values were calculated by non-linear regression analysis
using SigmaPlot 4.01 software.
HPLC analysis
The T47D cell suspension was prepared as described above and
450 ml was incubated with 0.1 mM [11, 12-
3H(N)]RA for 90 min.
After centrifugation for 10 min at 780 g, the supernatant was
analyzed for the presence of RA metabolites. Reverse-phase HPLC
analysis was carried out as described previously (Van heusden et al,
1998).
In vitro cytochrome P450 isozyme speciﬁcity
MetabolismofRAbyCYP26A1wasmeasuredinmicrosomesofT47D
human breast cancer cells that were pretreated for 16 h with 1 mM RA
to induce RA metabolism. Microsomes were prepared exactly as
describedbyHanandChoi(1996),andRAmetabolismwasmeasured
as described by Van Wauwe et al (1994). The conversion of androste-
nedione to estrone by aromatase (CYP19) in human placental
microsomes, the conversion of 17-hydroxy-20-dihydroprogesterone
to testosterone by 17,20-lyase (CYP17) in rat testicular S10 fractions,
and the 2a-, 7a-, 6b-, and 16b-hydroxylation of testosterone
(CYP2C11, CYP2A1, CYP3A, CYP2B1/2) in rat liver microsomes
were carried out as described (Vanden Bossche et al, 1990).
Proliferation experiments (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide assay)
T47D cells were seeded in Falcon
1 96-well cell culture plates (Life
Technologies, Merelbeke, Belgium) at 2500 cells per well in a total
volume of 150 ml. Cells were allowed to adhere to plastic for 24 h.
Drugs and/or medium were added to a ﬁnal volume of 200 ml (day
0). Cells were grown under these conditions for 7 days, with
renewal of medium and drugs on days 2 and 5. On day 7, medium
was renewed and 25 ml MTT-solution was added, and cells were
further incubated for 2 h in a cell incubator. The medium was
aspirated and 25 ml Sorensen glycine buffer (0.1 M glycine, 0.1 M
NaCl; pH 10.5) was added together with 100 ml DMSO to solubi-
lize the blue MTT-formazan product. After shaking for 10 min on
a microplate shaker, the absorbance at 540 nm was determined
using a Emax 96-well spectrophotometer (DPC, Grimbergen,
Belgium). Data are presented as mean+s.d. of three or four inde-
pendent experiments. Within an experiment, the result of each
experimental condition is the mean of six replicate wells. The
IC50-values were calculated by non-linear regression analysis using
SigmaPlot 4.01 software.
RT–PCR
T47D cells were seeded in Nunc
TM 6-well plates at a concentration
of 2610
6 cells per well in 5 ml medium. Cells were allowed to
adhere to plastic for 24 h. After indicated periods of time, total
RNA was isolated using UltraSpec-II (Biotecx Laboratories, TX,
USA) according to manufacturer’s instructions. Three micrograms
of total RNA was heated at 658C for 5 min and rapidly cooled on
ice. Then, 1500 ng oligo d(T)12–18 primer (Life Technologies, MD,
USA) was added and cDNA was synthesized using 200 U ml
71 M-
MLV RT (Life Technologies, MD, USA) in a RT reaction buffer
(Life Technologies, MD, USA) supplemented with 20 U ml
71
RNAsin (Life Technologies, MD, USA), and 500 mM each dNTP
(Perkin Elmer, CA, USA). The 60 ml reaction mixture was incu-
bated at 378C for 1 h, followed by a 4 min incubation at 908C
to inactivate the RT enzyme. Two microlitres of the RT reaction
mix was used for the PCR reaction. Ampliﬁcation was performed
in a total volume of 50 ml containing 2 ml cDNA, 5 ml1 0 6PCR
reaction buffer (Boehringer Mannheim, Germany), 1 ml sense
primer (20 mM), 1 ml antisense primer (20 mM), 4 ml dNTPs (each
at a concentration of 2.5 mM; Perkin Elmer, CA, USA) and
0.25 ml AmpliTaq Gold (5 U ml
71; Perkin Elmer, CA, USA).
AmpliTaq Gold was activated by a 10 min incubation at 948C.
The samples were then subjected to 30 or 24 cycles of ampliﬁcation
for CYP26A1 or b2-microglobulin, respectively. Each cycle
consisted of 1 min of denaturation at 928C, 1 min of annealing
at 558C (CYP26A1) or 508C( b2-microglobulin), and 2 min of
extension at 728C. At the end of the incubation an extra extension
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Figure 1 Chemical structure of R116010, [S-(R*,R*)]-N-[4-[2-(dimethy-
lamino)-1-(1H-imidazole-1-yl)propyl]-phenyl]-2-benzothiazolamine.
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products were separated on a 1.3% (w/v) agarose gel, and visua-
lized by UV light illumination after ethidium bromide staining.
Speciﬁc primers were obtained from Eurogentec (Seraing,
Belgium). Their sequences were as follows: CYP26A1 sense primer
5'-GCTGAAGAGTAAGGGTTTAC-3', and antisense primer 5'-CT-
TGGGAATCTGGTATCCAT-3' (yielding a PCR-product of
184 bp); b2-microglobulin sense primer 5'-ACCCCCACTGAAA-
AAGATGA-3', and antisense primer 5'-ATCTTCAAACCTCCAT-
GATG-3' (yielding a PCR product of 114 bp).
TA3-Ha mammary carcinoma model
Oestrogen-independent TA3-Ha murine mammary carcinoma cells
were grown by weekly intraperitoneal passage in vivo. Cells
(1.5610
6) were injected intraperitoneally in syngeneic A/J mice.
After 1 week, the peritoneum was rinsed with sterile saline and
the cells further diluted in MEM-Rega3 cell culture medium (Life
Technologies, Merelbeke, Belgium). The next in vivo passages
(1610
4 cells) were done in allogeneic C3D2F1 mice, but every
5th passage syngeneic A/J mice were used as the host. For the
current experiments, cells were used between in vivo passage 10–
20. Mice were subcutaneously inoculated with 1.5610
6 murine
mammary carcinoma TA3-Ha cells at day 0 and randomized into
the different experimental groups. Each group consisted of 10
animals for experiments with R116010 and of six animals for
experiments with RA. All treatments were performed by oral
gavage. Different doses of R116010 (1.25, 0.63, 0.31, 0.16,
0.08 mg kg
71 per dosage) and RA (5, 2.5, 1.25 mg kg
71 per
dosage) were administered on a twice-daily treatment regimen
given from day 1 until day 21. The control groups were given the
vehicle 20% 4-OH-b-cyclodextrine in sterile saline. Mice were daily
examined for adverse drug effects. At the end of the experiments,
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Figure 2 Reverse-phase HPLC analysis of radiolabelled RA metabolites
formed in T47D human breast cancer cells. T47D human breast cancer
cells were cultured under basal culture conditions (A) or pretreated with
1 mM RA (B, C). Then, cells were collected and incubated with 0.1 mM
[
3H]RA, either in the absence (A, B) or presence (C)o f1mM R116010.
Supernatants were analyzed by reverse-phase HPLC (10).
1 h 6 h 16 h
CYP26A1
b2-microglobulin
Control
10 -6 M
10 -8 M
10 -10 M
Control
10 -6 M
10 -8 M
10 -10 M
Control
10 -6 M
10 -8 M
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Figure 4 RT–PCR analysis of CYP26A1 mRNA expression after treatment with RA. T47D human breast cancer cells were treated with various con-
centrations of RA for indicated time periods. Thereafter, total RNA was prepared and subjected to RT–PCR. Ampliﬁed products were analyzed by agarose
gel electrophoresis with ethidium bromide staining.
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Figure 3 Inhibition of RA metabolism by R116010 and liarozole-fuma-
rate. T47D human breast cancer cells were pretreated with 1 mM RA to
induce RA metabolism. Concentration-response curves showing the inhibi-
tion by R116010 (*) and liarozole-fumarate (*) were determined using
the microcolumn assay as described in Materials and Methods. Results are
presented as mean+s.d. for R116010 (n=4) and liarozole-fumarate (n=3).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 605–611subcutaneous tumours were excised 24 h after the last treatment
and weighed to validate the antitumoural effects of the treatment.
Data are represented as box plots showing median group value, 25/
75th percentile, 10/90th percentile and outliers. Groups were statisti-
cally compared to the vehicle-treated groups using the Mann–
Whitney U-test. Signiﬁcance was deﬁned at the level of P50.05.
All animal experiments have been carried out with ethical
committee approval. The ethical guidelines that were followed meet
the standards required by the UKCCCR Guidelines.
RESULTS
R116010 is a potent inhibitor of RA metabolism
Human T47D breast cancer cells, cultured under control conditions,
are unable to metabolize RA into more polar metabolites (Figure
2A). After pretreatment for 16 h with 1 mM RA, T47D cells show
extensive RA metabolism (Figure 2B), converting RA into highly
polar metabolites (retention time: 3–10 min) and several metabo-
lites with intermediate polarity (retention time: 15–25 min),
including 4-OH-RA, and 16-OH-RA. RA metabolism is completely
inhibited by R116010 at a concentration of 1 mM (Figure 2C).
A concentration-response curve (Figure 3), as measured with the
quantitative microcolumn method, shows that R116010 inhibits the
formation of polar [
3H]RA metabolites with a calculated IC50-value
of 8.7+1.4 nM. In comparison, R116010 is over 100-fold more
potent than liarozole-fumarate, a previously identiﬁed inhibitor
of RA metabolism, that inhibits RA metabolism with an IC50-value
of 1.4 mM (Figure 3).
Auto-induction of RA metabolism correlates with
induction of CYP26A1
CYP26A1 is a cytochrome P450-dependent enzyme that speciﬁcally
metabolizes RA (White et al, 1997). Human T47D breast cancer
cells, cultured under control conditions, barely express detectable
CYP26A1 mRNA levels (Figure 4). CYP26A1 mRNA expression
levels can be induced in a concentration- and time-dependent
manner by treatment with RA (Figure 4). The expression levels
of CYP26A1 closely correlate with the observed enzyme activity
(Figure 2B and data not shown).
R116010 is a selective inhibitor of RA metabolism
The selectivity of R116010 towards CYP26A1 was tested by determin-
ing its inhibition proﬁle against other cytochrome P450-mediated
reactions. As shown in Table 1, R116010 inhibits CYP26A1-mediated
RA metabolism in microsomes from T47D cells with an IC50-value of
4n M. In contrast, even at high micromolar concentrations (10 mM),
R116010 barely inhibits other cytochrome P450-mediated reactions,
except for limited activity against 17,20-lyase (IC50=0.25 mM).
In comparison, liarozole-fumarate inhibits CYP26A1-mediated
RA metabolism at 100-fold higher concentrations (IC50=0.5 mM)
(Table 1). At this concentration liarozole-fumarate also clearly
inhibits other cytochrome P450-mediated reactions (Table 1).
R116010 enhances the antiproliferative activity of RA
RA inhibits T47D cell proliferation in a concentration-dependent
manner (Figure 5A,B) with a calculated IC50-value of
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Table 1 In vitro cytochrome P450 isozyme proﬁle for R116010 and liarozole-fumarate
R116010 Liarozole-fumarate
Activity Enzyme source CYP isozyme IC50 (mM)I C 50 (mM)
RA 4-hydroxylase T47D human breast cancer microsomes CYP26A1 0.004 0.5
Aromatase Human placental microsomes CYP19 410 (12)
a 0.003
17,20-lyase Rat testicular S10 fraction CYP17 0.25 0.11
Testosterone 2a-hydroxylase Rat liver microsomes CYP2C11 410 (28)
a 2.9
Testosterone 7a-hydroxylase Rat liver microsomes CYP2A1 410 (12)
a 410
Testosterone 6b-hydroxylase Rat liver microsomes CYP3A 410 (41)
a 0.4
Testosterone 16b-hydroxylase Rat liver microsomes CYP2B1/2 410 (21)
a 0.5
aValues between parentheses represent percentage of inhibition of 10 mM R116010.
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Figure 5 Concentration-response curves showing the antiproliferative
effects of (A)R A( &), R116010 (&) and RA in combination with
R116010 (*: 0.01 mM; *: 0.1 mM; ~:1mM)o r( B)R A( &), liarozole-fu-
marate (&) and RA in combination with liarozole-fumarate (*: 0.1 mM; *:
1 mM; ~:1 0mM) in T47D cells. Cell proliferation was measured after 7
days using a MTT-based assay as described in detail in Materials and Meth-
ods. Results are presented as mean+s.d. for R116010 (n=4) and liarozole-
fumarate (n=3).
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proliferation (Figure 5A). However, in combination with RA,
R116010 enhances the antiproliferative activity of RA in a concen-
tration-dependent manner (Figure 5A). At a concentration of
0.01 mM R116010 enhances the antiproliferative activity of RA by
1.25-fold (IC50-value=1.6+0.6 nM), at 0.1 mM R116010 by 2.6-fold
(IC50-value=0.77+0.18 nM) and at 1 mM R116010 by three-fold
(IC50-value=0.62+0.19 nM).
In contrast, liarozole-fumarate, tested up to a concentration
of 10 mM, is unable to enhance the antiproliferative activity of
RA (Figure 5B). At this concentration (10 mM), liarozole-fuma-
rate by itself decreases T47D cell proliferation by
approximately 25% (Figure 5B). This decrease in T47D cell
proliferation at 10 mM explains the apparent enhancement of
RA activity, which is actually the effect of liarozole-fumarate
alone (Figure 5B).
R116010 inhibits the growth of murine TA3-Ha mammary
tumours in vivo
Mice subcutaneously inoculated with oestrogen-independent TA3-
Ha cells were treated twice-daily with RA (Figure 6A) or
R116010 (Figure 6B) from day 1 until day 21. As shown in Figure
6A, RA inhibits TA3-Ha tumour growth in a dose-dependent
manner. The lowest active dose is 2.5 mg kg
71. At a dose of
5m gk g
71, mice lost 5% of body weight (data not shown) and
toxicity was observed, which consisted mainly of hair loss, and
impaired movement due to bone fractures.
R116010 potently inhibits TA3-Ha tumour growth at doses as
low as 0.16 mg kg
71 (Figure 6B). R116010 is approximately 60-
fold more potent than liarozole-fumarate which in this model inhi-
bits tumour growth only at 10 mg kg
71 (data not shown).
Toxicity, related to hypervitaminosis A, was observed at a dose
of 5 mg kg
71 for R116010 and at 20 mg kg
71 for liarozole fuma-
rate. At these doses hair loss and bone fractures were observed, and
body weight decreased by *15% (data not shown).
DISCUSSION
The prompt emergence of resistance to RA treatment is a major
hurdle in the clinical development of RA (Muindi et al, 1992; Mill-
er, 1998). Drugs which are able to inhibit RA metabolism may
therefore prove valuable in the treatment of cancer. In this study,
we have identiﬁed R116010 as a highly potent and selective inhibi-
tor of RA metabolism.
Human breast T47D carcinoma cells are known to have an
inducible RA metabolism (Han and Choi, 1996; Van der Leede
et al, 1997). The capacity to metabolize RA closely correlates with
the expression level of CYP26A1, a cytochrome P450-dependent
enzyme that speciﬁcally metabolizes RA (White et al, 1997). In
untreated T47D cells, which are unable to metabolize RA,
CYP26A1 expression is barely detectable. Treatment with RA
rapidly induces the capacity to metabolize RA (Han and Choi,
1996), which is correlated with a strong induction of CYP26A1,
in agreement with a previous report (Sonneveld et al, 1998). In
intact T47D cells, R116010 potently inhibits RA metabolism with
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Figure 6 In vivo antitumour activity of RA (A) and R116010 (B) in the murine TA3-Ha tumour model. TA3-HA mammary carcinoma cells (1.5610
6)
were subcutaneously inoculated in mice. RA (A) or R116010 (B) was given by oral treatment twice daily from day 1 until day 21. Tumours were excised
24 h after the last treatment and weighed. Data are represented as box plots showing median group value, 25/75th percentile, 10/90th percentile and out-
liers. Groups were statistically compared to the vehicle-treated groups using the Mann–Whitney U-test. Statistical signiﬁcance was deﬁned at the level of
*P50.05.
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more potent than liarozole-fumarate, a previously identiﬁed inhibi-
tor of RA metabolism (Wouters et al, 1992).
As well as being a more potent inhibitor of RA metabolism,
R116010 is also more selective as compared to liarozole-fumarate.
Although our in vitro data suggest that R116010 might affect
androgen levels by inhibiting 17,20-lyase, no change on blood
hormone levels could be detected in rats treated with a high dose
(10 mg kg
71) of R116010 (data not shown). Liarozole-fumarate is
much less speciﬁc. It is a potent aromatase inhibitor (Bruynseels et
al, 1990), and in addition it also inhibits other cytochrome P450-
mediated reactions, thereby affecting hormone levels both in
animals and in humans (Bruynseels et al, 1990). Taken together,
these data suggest that R116010 is less likely to produce adverse
side effects.
In T47D cell proliferation experiments, R116010 enhances the
antiproliferative activity of RA in a concentration-dependent
manner. Concentrations effective in enhancing the biological activ-
ity of RA, are identical to the concentrations that are needed to
inhibit RA metabolism in intact cells. Therefore, these data support
the hypothesis that R116010 enhances the biological activity of RA
through inhibition of RA metabolism. Liarozole-fumarate is unable
to enhance the antiproliferative activity of RA in T47D cells. This is
in contrast to our previous data, which clearly showed that liaro-
zole-fumarate is able to enhance both the antiproliferative and
differentiation-inducing activity of RA in MCF-7 human breast
cancer cells (Wouters et al, 1992; Van heusden et al, 1996). This
apparent contradiction might be explained by the fact that T47D
cells are known to metabolize RA at a much higher rate than
MCF-7 cells (Van der Leede et al, 1997; unpublished results) and
that liarozole-fumarate is therefore not potent enough to effectively
inhibit RA metabolism in T47D cells.
In vivo, R116010 has been shown to inhibit the growth of ortho-
topically implanted androgen-independent rat prostatic Dunning
R3327/PIF-1 carcinoma cells (Van Ginckel et al, 1999), and of
subcutaneous mouse Lewis lung (3LL) tumours (Smets et al,
manuscript in preparation). In this study, the in vivo activity of
R116010 has been evaluated in the murine oestrogen-independent
TA3-Ha mammary carcinoma model. An oestrogen-independent
model was chosen to exclude any hormonal mechanism of action.
In addition, TA3-Ha cells are known to actively metabolize RA
(Garrabrant and End, 1995) and TA3-Ha tumours are sensitive
to RA treatment (Wouters et al, 1990). Indeed, treatment with
RA inhibits TA3-Ha tumour growth in a dose-dependent manner.
However, keeping in mind that the lowest active dose is
2.5 mg kg
71 and that the maximum tolerable dose is 5 mg kg
71,
RA does not show a real therapeutic window. Similarly, liaro-
zole-fumarate has no therapeutic window since a dose of
10 mg kg
71 has to be used to induce antitumour activity, and
the maximum tolerated dose is 20 mg kg
71 (data not shown). In
sharp contrast, R116010 inhibits TA3-Ha tumour growth at doses
as low as 0.16 mg kg
71. With a maximum tolerated dose of
5m gk g
71, R116010 exhibits a 30-fold therapeutic window. We
speculate that this larger therapeutic window is due to the intratu-
moural action of R116010, thereby increasing intracellular levels of
RA, while RA mainly remains in the circulation, and much higher
doses are needed to produce a biological response. Given that
R116010 has a broader therapeutic window, one can argue that
R116010 may be a more effective anticancer drug. The observation
of retinoid-like side effects at higher doses reinforces the hypothesis
that R116010 exerts its antitumour activity via RA.
In conclusion, R116010 has been identiﬁed as a potent and
selective inhibitor of RA metabolism. Inhibition of RA metabolism
leads to an enhancement of the antiproliferative activity of RA both
in vitro and in vivo. Inhibitors of RA metabolism may therefore
represent a novel class of anticancer agents.
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